| Literature DB >> 25642760 |
Arie O Verkerk1, Ronald Wilders2.
Abstract
Since 2003, several loss-of-function mutations in the HCN4 gene, which encodes the HCN4 protein, have been associated with sinus node dysfunction. In human sinoatrial node (SAN), HCN4 is the most abundant of the four isoforms of the HCN family. Tetramers of HCN subunits constitute the ion channels that conduct the hyperpolarization-activated "funny" current (If), which plays an important modulating role in SAN pacemaker activity. Voltage-clamp experiments on HCN4 channels expressed in COS-7, CHO and HEK-293 cells, as well as in Xenopus oocytes have revealed changes in the expression and kinetics of mutant channels, but the extent to which especially the kinetic changes would affect If flowing during a human SAN action potential often remains unresolved. In our contribution to the Topical Collection on Human Single Nucleotide Polymorphisms and Disease Diagnostics, we provide an updated review of the mutation-induced changes in the expression and kinetics of HCN4 channels and provide an overview of their effects on If during the time course of a human SAN action potential, as assessed in simulated action potential clamp experiments. Future research may solve apparent inconsistencies between data from clinical studies and data from in vitro and in silico experiments.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25642760 PMCID: PMC4346881 DOI: 10.3390/ijms16023071
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic topology of the HCN4 and MiRP1 proteins. The HCN4 α-subunit has six transmembrane segments (S1–S6), a pore-forming loop (P) and intracellular N- and C-termini. The voltage sensor of the channel is formed by the positively-charged S4 helix. The C-terminus comprises the C-linker (dotted line) and the cyclic nucleotide-binding domain (cNBD), which is known to mediate cyclic AMP (cAMP)-dependent changes in HCN channel gating. The MiRP1 β-subunit has a single transmembrane segment with an extracellular N-terminus and intracellular C-terminus. Red dots indicate the location of the 23 known HCN4 and MiRP1 mutation sites associated with clinically established or potential sinus node dysfunction. The split dots indicate the truncations resulting from the 573X and 695X non-sense (truncating) mutations.
Clinical observations in carriers of mutations in HCN4 or KCNE2.
| Mutation | Mutation Carriers | Clinical Presentation | Study | |
|---|---|---|---|---|
| P257S | single index patient (65-year-old male) | diagnosed with paroxysmal AF at age 29; AF became permanent at age 43 years; sinus node dysfunction during ajmaline test in proband and proband’s father; 73 pauses >2.0 s on 24-h Holter monitoring | Macri | |
| A414G | 3 members of a single family | AF and LVNC in 74-year-old male index patient; combined sinus bradycardia and LVNC in his two mutation-carrying sons; severe sinus bradycardia involving 12 episodes of standstill on Holter monitoring in one of the sons | Milano | |
| G480R | 8 members of a single family | asymptomatic sinus bradycardia from a young age, with normal chronotropic and exercise capacity; minimum, average and maximum heart rates of 31 ± 8, 48 ± 12 and 101 ± 21 beats/min, respectively, in the 8 mutation carriers | Nof | |
| Y481H | 4 members of two families with a common ancestral haplotype | combined sinus bradycardia and LVNC; frequent episodes of severe bradycardia (heart rate < 30 beats/min) and pacemaker implantation in the index patient of the first family; severe sinus bradycardia (40 beats/min) in the index patient of the second family and pacemaker implantation in his mutation-carrying mother because of bradyarrhythmias | Milano | |
| G482R | 6 members of a single family | combined sinus bradycardia and LVNC; pacemaker implanted in three mutation carriers because of bradycardia-related symptoms (average heart rate of 46 beats/min); MVP in two individuals | Milano | |
| G482R | 3 members of a single German family | combined sinus bradycardia, LVNC, and MVP; minimum and average heart rates of 21 and 34 beats/min, respectively, and pacemaker implantation in the index patient | Schweizer | |
| A485V | 14 members of three Moroccan Jewish decent families | symptomatic familial sinus bradycardia with normal chronotropic and exercise capacity; minimum, average and maximum heart rates of 37 ± 3, 58 ± 6 and 117 ± 27 beats/min in the 14 mutation carriers, respectively, | Laish-Farkash | |
| K530N | 6 members of a single family | mild, asymptomatic sinus bradycardia (50–60 beats/min) in the index patient; familial age-dependent tachycardia-bradycardia syndrome and persistent AF; no AF or any other relevant cardiac arrhythmia in non-carriers | Duhme | |
| D553N | single index patient (43-year-old female) and two family members | wide spectrum of cardiac arrhythmias, including severe bradycardia (24-h average of 39 beats/min), QT prolongation and | Ueda | |
| 573X | single index patient (66-year-old female) | idiopathic sinus bradycardia of 41 beats/min; chronotropic incompetence; intermittent episodes of AF | Schulze-Bahr | |
| S672R | 15 members of a single Italian family | asymptomatic sinus bradycardia; average resting heart rate, corrected for age and gender, of 52.2 ± 1.4 beats/min (range 43–60 beats/min), in the 15 mutation carriers | Milanesi | |
| 695X | 8 members of a single German family | marked sinus bradycardia with no signs of chronotropic incompetence; basal heart rate of 45.9 ± 4.6 beats/min (range 38–51 beats/min) in the 8 mutation carriers | Schweizer | |
| P883R | single male patient | sinus bradycardia (35 to 40 beats/min), paroxysmal AF (tachycardia-bradycardia syndrome) and LVNC; pacemaker implantation | Schweizer | |
| G1097W | single index patient (69-year-old male) | complete AV block with wide QRS, but no sinus nodal dysfunction; atrial rate of 132 beats/min; ventricular rate of 33 beats/min; pacemaker implantation at the age of 51 years | Zhou | |
| M54T | single index patient (55-year-old Caucasian male) | history of marked sinus bradycardia; average heart rate of 43 beats/min (range 30–125 beats/min), along with pauses; daughter died suddenly at the age of 13, and post-mortem genetic testing revealed the M54T mutation | Nawathe | |
Mutations are heterozygous with autosomal dominant inheritance. AF, atrial fibrillation; LVNC, left ventricular non-compaction cardiomyopathy; MVP, mitral valve prolapse; QT prolongation, prolongation of the rate-corrected QT interval on the electrocardiogram.
Effect of mutations and variants in HCN4 or KCNE2 on HCN4 current.
| Mutation | Type of Expression | Expression System | Shift in V1/2 or Activation Threshold (mV) | Slope Factor (mV) | Time Constant of Activation | Time Constant of Deactivation | Reversal Potential | Full-Activated Current Density | Channel Expression | Sensitivity to cAMP | Reference |
|---|---|---|---|---|---|---|---|---|---|---|---|
| K189R | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| P257S | heteromeric | CHO | = | = | ? | ? | ? | = | ≈50% | ? | Macri |
| homomeric | CHO | 0% | ↓ | Macri | |||||||
| A414G | heteromeric | CHO | −23.9 | = | ? | ? | ? | = | ? | ? | Milano |
| G480R | heteromeric | oocyte, HEK | ≈−15 | ? | ↑ a | ? | = | ≈50% | ? | = b | Nof |
| homomeric | oocyte, HEK | ≈−30 | ? | ↑ a | ? | = | ≈12% | ↓ | = b | Nof | |
| oocyte | ? | ? | ? | ? | ? | ≈20% | ? | ? | Laish-Farkash | ||
| Y481H | heteromeric | CHO | −43.9 | = | ? | ? | ? | = | ? | ? | Milano |
| G482R | heteromeric | HEK | = | = | = | = | = | 35% | = | ? | Schweizer |
| CHO | −38.7 | = | ? | ? | ? | = | ? | ? | Milano | ||
| homomeric | HEK | ? | ? | ? | ? | ? | 6% | = | ? | Schweizer | |
| A485V | heteromeric | oocyte, HEK | ≈−30 | ? | ↑ a | ↑ a | = | ≈33% | = | ? | Laish-Farkash |
| homomeric | oocyte, HEK | ≈−60 | ? | ↑ a | ↑ a | = | ≈5% | = | ↓ | Laish-Farkash | |
| K530N | heteromeric | HEK | ≈−14 | = | 237% | = | = | = | ? | ↑ | Duhme |
| homomeric | HEK | = | = | = | = | = | = | ? | = | Duhme | |
| D553N | heteromeric | COS | = | = | ≈90% | ≈110% | ? | ≈37% | ↓ | ? | Ueda |
| oocyte, COS | ? | ? | ? | ? | ? | ≈54% | = | ? | Netter | ||
| homomeric | COS | = | = | ≈90% | ≈110% | ? | ≈8% | ↓ | ? | Ueda | |
| oocyte, COS | = | = | = | = | ? | ≈12% | = | ↓ | Netter | ||
| 573X | heteromeric | COS | = c | −1.9 c | = | ? | ? | ? | = | ↓ | Schulze-Bahr |
| homomeric | COS | −4.6 c | = | = | ? a | ? | ? | = | ↓ | Schulze-Bahr | |
| S672R | heteromeric | HEK | −4.9 | = | = | ≈74% | ? | ? | ? | ? | Milanesi |
| homomeric | HEK | −8.4 | = | = | ≈63% | ? | ? | ? | = | Milanesi | |
| oocyte | −6.1 | ? | ≈180% | ≈90% | ? | ? | ? | ↓ | Xu | ||
| N688S | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| 695X | heteromeric | HEK | = | = | = | ? | ? | = | ? | ↓ | Schweizer |
| homomeric | HEK | = | −3.5 | 72% | = | = | ? | ? | ↓ | Schweizer | |
| T822M | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| G885R | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| P945S | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| A1045V | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| R1068H | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| G1077S | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| G1097W | heteromeric | CHO | −7.6 | = | ? | 81% | ? | 55% | ? | ? | Zhou |
| homomeric | CHO | −12 | = | ? | 79% | ? | 47% | ? | = | Zhou | |
| E1193Q | homomeric | CHO | = | = | ? | ? | ? | = | ? | ? | Macri |
| M54T | homomeric | NRVM | = | = | 192% | = | ? | 18% | ? | ? | Nawathe |
Data are the changes relative to wild-type current. ?, not reported; ≈, estimated from presented figures; ↓, decreased; ↑, increased; =, unchanged. a Changes reported, but no quantitative data provided; b performed in oocytes, which lack cAMP modulation, due to high basal activity [21]; c with 15-s hyperpolarizing pulses (at 20–22 °C); oocyte, HEK, COS and NRVM: Xenopus oocytes, HEK-293 cells, COS-7 cells and neonatal rat ventricular cardiomyocytes, respectively.
Figure 2Membrane currents of a human sinoatrial node (SAN) pacemaker cell assessed by a simulated action potential clamp. (A) Action potentials recorded from a human SAN pacemaker cell used for the action potential clamp; (B) associated rate of change of the membrane potential (dVm/dt); (C) global intracellular calcium concentration ([Ca2+]i) in a different cell with a highly similar cycle length; and (D) numerically reconstructed membrane current (Im): L-type calcium current (ICa,L), If, delayed rectifier potassium current (IKr) and net membrane current (Inet). See the text for details.
Figure 3Effect of mutations in HCN4 on If in a human SAN pacemaker cell assessed by simulated action potential clamp. (A) Action potentials recorded from a human SAN pacemaker cell used for action potential clamp; (B) computed wild-type (WT) If of a human SAN pacemaker cell during the action potentials of (A) under control conditions (“control”, blue line) and upon adrenergic stimulation (“cAMP”, red line); (C–H) computed If of a human SAN pacemaker cell carrying heterozygous mutation in HCN4, as indicated, during the action potentials of (A) under control conditions (solid blue line) and upon adrenergic stimulation (solid red line). Wild-type If of (B) under control conditions (dashed blue line) and upon adrenergic stimulation (dashed red line) are shown for reference. G482R traces, labelled “a” and “b”, are based on data from Milano et al. [27] and Schweizer et al. [28], respectively.
Figure 4Contribution of If to diastolic depolarization for each of the heterozygous mutations in HCN4 or KCNE2. The charge carried by If (Qf) during the 25-mV, 550-ms spontaneous depolarization from the maximum diastolic potential of −63 mV of the human SAN action potential is as indicated in Figure 3A. The blue bars are computed from the If traces under control conditions (“control”). The red bars are computed from the If traces upon adrenergic stimulation (“cAMP”). The dashed grey line indicates the charge of 0.025 pC/pF carried by the net membrane current (Qnet) during the 25-mV depolarization. (A) Mutations of Figure 3; (B) mutations assessed in previous publication [30].
Parameter settings in simulated action potential clamp experiments.
| Mutation | Scaling Factor for | Shift (mV) | Shift with cAMP (mV) |
|---|---|---|---|
| 0.50 | 0 | +15 | |
| 1 | −23.9 | −8.9 | |
| 0.50 | −15 | 0 | |
| 1 | −43.9 | −28.9 | |
| 1 | −38.7 | −23.7 | |
| 0.35 | 0 | +15 | |
| 0.33 | −30 | −15 | |
| 1 | −14 | +7.8 | |
| 0.37 | 0 | +15 | |
| 1 | 0 | 0 | |
| 1 | −4.9 | +10.1 | |
| 1 | 0 | 0 | |
| 0.55 | −7.6 | +7.4 | |
| 0.18 | 0 | +15 |
Scaling factor and shifts relative to the wild-type. Shifts applied to both the steady-state activation curve and time constant curve. a According to Milano et al. [27]; b according to Schweizer et al. [28].